By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468

NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.

Key Statistics

Ownership: Public

Web Site: NovaBay Pharmaceuticals, Inc.
Symbol: NBY

Company News
NovaBay Pharmaceuticals, Inc. (NBY) Signs Distribution Agreement With The Biopharm Group 12/8/2014 2:33:46 PM
White Paper Describes NovaBay Pharmaceuticals, Inc. (NBY)’s Non-Antibiotic Anti-Infective Portfolio 11/24/2014 8:48:25 AM
NovaBay Pharmaceuticals, Inc. (NBY) Signs Distribution Agreement With McKesson Corporation For i-Lid Cleanser 11/17/2014 11:41:20 AM
NovaBay Pharmaceuticals, Inc. (NBY) Reports Third Quarter 2014 Financial Results And A Clinical/Business Update 11/12/2014 8:04:33 AM
NovaBay Pharmaceuticals, Inc. (NBY) Receives 2nd Major NeutroPhase Order For 150,000 Units From China Pioneer Pharma 10/27/2014 11:28:31 AM
NovaBay Pharmaceuticals, Inc. (NBY) Expands I-Lid Cleanser Market Reach With Addition To Vision Source Network 10/9/2014 10:39:16 AM
NovaBay Pharmaceuticals, Inc. (NBY) Receives First Large NeutroPhase Order From China Pioneer Pharma 9/25/2014 2:23:11 PM
NovaBay Pharmaceuticals, Inc. (NBY) Creates Optometry Advisory Board 9/18/2014 10:57:27 AM
NovaBay Pharmaceuticals, Inc. (NBY) Will Feature i-Lid Cleanser For The First Time At Vision Expo West 9/16/2014 12:55:23 PM
NovaBay Pharmaceuticals, Inc. (NBY) To Present At Rodman & Renshaw16th Annual Healthcare Conference 9/5/2014 12:05:17 PM